Abstract
Metoprolol CR/ZOK (controlled release, zero order kinetics) is a new formulation of an extensively used β1-selective, β-adrenoceptor blocking drug, (β1,-blocker), designed to provide continuous, even, plasma concentrations in the therapeutic range. It should, therefore, provide an effective well-tolerated treatment for hypertension and angina pectoris and for use in secondary prevention following a myocardial infarct. The purpose of this review is to consider the need for such a formulation, to describe its pharmaceutical development, review its pharmacology and assess its efficacy and tolerability compared with other available agents.

This publication has 46 references indexed in Scilit: